The Joint (JYNT) Q2 2025 earnings summary

Executive summary

• Transitioned to a pure-play franchisor by refranchising 37 clinics in Q2 2025, reducing corporate-owned clinics to 8% and bringing the total to 92% franchised.

• System-wide sales grew 2.6% to $129.6 million, with comparable sales up 1.4% year-over-year.

• Launched a new pain relief-focused brand campaign, mobile app, and dynamic revenue management to enhance patient experience and retention.

• Leadership strengthened with a new CFO, two new board members, and a focus on digital marketing and SEO optimization.

• Sale of 31 clinics in Arizona and New Mexico for $11.1 million, with the buyer agreeing to open 10 additional clinics.

Financial highlights

• Revenue from continuing operations increased 5% to $13.3 million in Q2 2025.

• Consolidated adjusted EBITDA grew 52% to $3.2 million compared to Q2 2024.

• Net income was $93,000, reversing a net loss of $3.6 million in the prior year.

• Unrestricted cash and equivalents at quarter-end were $29.8 million.

• General and administrative expenses decreased 1% to $7.7 million.

Outlook and guidance

• 2025 system-wide sales guidance revised to $530–$550 million, down from $550–$570 million.

• Comp sales now expected to increase in the low single-digit range, versus prior mid-single-digit guidance.

• Adjusted EBITDA guidance raised to $10.8–$11.8 million, up from $10–$11.5 million.

• New franchise clinic openings expected at 30–35, down from 57 in 2024.